Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates

Ying Poi Liu, PhD, Jacek Lubelski, PhD, Erich Ehlert, PhD, Sander Gielen, PhD, Paula Miranda, PhD, Martin de Haan, Bart Nijmeijer, PhD, Harald Petry, PhD

Blood (2017) 130 (Supplement 1): 2058.

https://doi.org/10.1182/blood.V130.Suppl_1.2058.2058

Published: 2017

Journal Articles

Safety and Efficacy of an Adeno Associated Virus-Based Vector Carrying the Human Clotting Factor IX Gene (AAV5-hFIX) As Studied in Non-Human Primates

Bart Nijmeijer, PhD, Harald Petry, PhD, Lisa Spronck, Corina Van Der Kruijssen, Jorgen Petersen, MD PhD, Florence Salmon, PhD

Blood (2014) 124 (21): 4800.

https://doi.org/10.1182/blood.V124.21.4800.4800

Published: 2014

Journal Articles

Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B

Wolfgang A. Miesbach, MD PhD, Christian Meyer, MD PhD, Bart Nijmeijer, PhD, Florence Salmon, PhD, Nadina Grosios, PhD, Harald Petry, PhD, Frank W.G. Leebeek, MD PhD

Blood (2014) 124 (21): 5948.

https://doi.org/10.1182/blood.V124.21.5948.5948

Published: 2014

Journal Articles

IL-7 receptor expression identifies suicide gene–modified allospecific CD8 + T cells capable of self-renewal and differentiation into antileukemia effectors

Attilio Bondanza, Lothar Hambach, Zohara Aghai, Bart Nijmeijer, Shin Kaneko, Sara Mastaglio, Marina Radrizzani, Katharina Fleischhauer, Fabio Ciceri, Claudio Bordignon, Chiara Bonini, Els Goulmy

Blood (2011) 117 (24): 6469–6478.

https://doi.org/10.1182/blood-2010-11-320366

Published: 2011

Includes: Supplemental data

Journal Articles

Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody Combination Therapy.

Bart Nijmeijer, PhD, Marianke LJ Van Schie, Henriette maria Goselink, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 835.

https://doi.org/10.1182/blood.V114.22.835.835

Published: 2009

Journal Articles

Cytotoxicity Is Not Required for the Anti-Leukemia Efficacy of Human H-Y-Specific CD4+ T Lymphocytes In Vivo.

Attilio Bondanza, MD, PhD, Lothar Hambach, MD, Zohara Aghai, MSc, Monica Casucci, BSc, Bart Nijmeijer, PhD, Fabio Ciceri, MD, Chiara Bonini, MD, Els Goulmy, PhD

Blood (2009) 114 (22): 3553.

https://doi.org/10.1182/blood.V114.22.3553.3553

Published: 2009

Journal Articles

Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia.

Sanja Stevanovic, Bart Nijmeijer, PhD, Marianke LJ Van Schie, Roelof Willemze, MD, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 1330.

https://doi.org/10.1182/blood.V114.22.1330.1330

Published: 2009

Journal Articles

Human Alloreactive CD4+ T Cells as Potent Effector Cells and Sole Mediators of Anti-Tumor Responses in a NOD/SCID Mouse Model for Human Acute Leukemia.

Sanja Stevanovic, Marieke Griffioen, PhD, Marianke LJ Van Schie, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Bart Nijmeijer, PhD

Blood (2008) 112 (11): 1245.

https://doi.org/10.1182/blood.V112.11.1245.1245

Published: 2008

Journal Articles

Focal Deletion of Genes Involved in the Control of Cell Cycle Progression Contributes to Growth Factor Independence in Acute Lymphoblastic Leukemia Cells

Bart Nijmeijer, PhD, Karoly Szuhai, MD, PhD, Henriette M Goselink, Marianke LJ Van Schie, Danielle De Jong, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2008) 112 (11): 789.

https://doi.org/10.1182/blood.V112.11.789.789

Published: 2008

Journal Articles

Requirements for Retroviral Targeting of a Suicide Gene to Alloreactive Memory Stem T Cells for Adoptive Immunotherapy of Leukemia.

Attilio Bondanza, MD, PhD, Lothar Hambach, MD, Shin Kaneko, MD, PhD, Sara Mastaglio, MD, Bart Nijmeijer, PhD, Astrid Van Halteren, PhD, Maurilio Ponzoni, MD, Luca Aldrighetti, MD, Salvatore Toma, PhD, Marina Radrizzani, BSc, Fabio Ciceri, MD, Claudio Bordignon, MD, Els Goulmy, PhD, Chiara Bonini, MD

Blood (2007) 110 (11): 2176.

https://doi.org/10.1182/blood.V110.11.2176.2176

Published: 2007

Journal Articles

Rituximab and Alemtuzumab in Combination, but Not Alone, Induce Complete Remissions in a Preclinical Animal Model of Primary Human ALL: Rationale for Combination Treatment.

Bart Nijmeijer, PhD, Marianke L.J. van Schie, Roel Willemze, PhD, J.H. Frederik Falkenburg, PhD

Blood (2007) 110 (11): 2833.

https://doi.org/10.1182/blood.V110.11.2833.2833

Published: 2007

Journal Articles

Establishment and Characterization of a tel/abl Rearrangement Responsible for Imatinib Sensitivity in bcr/abl Negative Acute Lymphoblastic Leukemia.

Jörg Bäumler, PhD, J.H. Frederik Falkenburg, PhD, Marianke L.J. van Schie, Karoly Szuhai, PhD, Martine Pape, Sina Droll, Oliver G. Ottmann, PhD, Bart Nijmeijer, PhD

Blood (2007) 110 (11): 4280.

https://doi.org/10.1182/blood.V110.11.4280.4280

Published: 2007

Journal Articles

Upregulation of CD20 on Human Acute Lymphoblastic Leukemia Cells by IL-4 and CpG Motif Containing Oligonucleotides Increases Susceptibility to Rituximab.

Bart Nijmeijer, Marianke L.J. Van Schie, Roelof Willemze, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 1879.

https://doi.org/10.1182/blood.V108.11.1879.1879

Published: 2006

NARROW

Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates

Safety and Efficacy of an Adeno Associated Virus-Based Vector Carrying the Human Clotting Factor IX Gene (AAV5-hFIX) As Studied in Non-Human Primates

Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B

IL-7 receptor expression identifies suicide gene–modified allospecific CD8 + T cells capable of self-renewal and differentiation into antileukemia effectors

Cytotoxicity Is Not Required for the Anti-Leukemia Efficacy of Human H-Y-Specific CD4+ T Lymphocytes In Vivo.

Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia.

Human Alloreactive CD4+ T Cells as Potent Effector Cells and Sole Mediators of Anti-Tumor Responses in a NOD/SCID Mouse Model for Human Acute Leukemia.

Focal Deletion of Genes Involved in the Control of Cell Cycle Progression Contributes to Growth Factor Independence in Acute Lymphoblastic Leukemia Cells

Requirements for Retroviral Targeting of a Suicide Gene to Alloreactive Memory Stem T Cells for Adoptive Immunotherapy of Leukemia.

Rituximab and Alemtuzumab in Combination, but Not Alone, Induce Complete Remissions in a Preclinical Animal Model of Primary Human ALL: Rationale for Combination Treatment.

Establishment and Characterization of a tel/abl Rearrangement Responsible for Imatinib Sensitivity in bcr/abl Negative Acute Lymphoblastic Leukemia.

Upregulation of CD20 on Human Acute Lymphoblastic Leukemia Cells by IL-4 and CpG Motif Containing Oligonucleotides Increases Susceptibility to Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only